This report explores barriers limiting the adoption of precision oncology despite major advances in targeted therapies and diagnostics. It identifies gaps across biomarker testing, data infrastructure, reimbursement, clinical workflows, and patient access. While precision medicines improve outcomes by matching therapies to tumor characteristics, uneven access to testing and fragmented care pathways delay treatment decisions. The report highlights disparities by geography and healthcare system design and stresses the importance of integrated diagnostics, data-sharing frameworks, and coordinated stakeholder action. It concludes that realizing the promise of precision oncology requires system-level change beyond drug innovation alone.

Join for free to read